Bayer plans second H1 2013 filing for riociguat, this time in CTEPH
This article was originally published in Scrip
Executive Summary
Bayer Healthcare is planning to submit an application for marketing authorisation during the first half of 2013 for its first-in-class guanylate cyclase stimulator vasodilator, riociguat, in a second indication - chronic thromboembolic pulmonary hypertension (CTEPH).